The study is for patient that are receiving camizestrant as a treatment. The main purpose of study is to change the dosage of camizestrant from 150mg to 75mg. This change was prompted by updated, emerging data from ongoing studies showing
no difference in efficacy between the 75 mg and 150 mg doses. Subject can expect to be in this study for up to 24 months.

This study is for female participants who have a history of stage 0-III breast cancer diagnosis. The main purpose of this study is to determine which combination of intervention components is expected to produce the greatest benefit to survivors for the least intervention burden. Participants can expect to be in this study for up to 12 months.

This study is for patients that are breast cancer survivors suffering from cancer-related cognitive impairment. This study is being done to determine if breast cancer survivors suffering from cancer-related cognitive impairment have improvement in concentrating, learning new things, remembering, and making decisions by receiving computerized cognitive training. Patients can expect to be in the study 6 months.

This study is for patients that have been diagnosed with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III breast cancer. The drug being used Durvalumab, Cyclophospharmide, Doxorubicin, and Paclitaxel. The study is being done to compare breast cancer event-free survival between patients randomized to standard of care neoadjuvant chamotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab. Patients are expected to be in the study for XXmonths.